A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Locally Advanced and Metastatic Urothelial Carcinoma

PHASE1/PHASE2UnknownINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 10, 2018

Primary Completion Date

February 14, 2020

Study Completion Date

June 23, 2023

Conditions

Urothelial Carcinoma

Interventions

DRUG

ZKAB001 5mg/kg

5mg/kg/times bi-week IV administration of ZKAB001

DRUG

ZKAB001 10mg/kg

10mg/kg/times bi-week IV administration of ZKAB001

DRUG

ZKAB001 15mg/kg

15mg/kg/times bi-week IV administration of ZKAB001

Trial Locations (1)

RECRUITING

Beijing Tumor Hospital, Beijing